|Status : Upcoming||Report Code : VRHC1067||Industry : Healthcare||Available Format :|
Human recombinant insulin is the synthetic insulin, resulted utilizing recombinant DNA technology. The global human recombinant insulin market is growing at significant rate, due to mounting occurrence diabetes and mounting need for human insulin analogs. Different product type contributed to the human recombinant insulin market size. The market has witnessed high demand for long acting human insulin in the coming years due to advanced competence and capability to pose constant insulin delivery during the day.
Insight by Product Type
The various types of products offered in the market are rapid-acting, long-acting, short-acting, premixed, and intermediate-acting. Of all product type, long-acting human insulin segment is expected to grow at the fastest rate in the market due to advanced competence and capability to pose constant insulin delivery during the day.
Insight by Brand
On the basis of brand, the market is subdivided into Humalog, Lantus, Novolog, Novorapid, Apidra, Humulin, Novolin, Levemir and others. Of all the brands, the Lantus accounted the foremost share in the human recombinant insulin market. In addition, Levemir and Apidra are expected to grow at fastest rate in the market.
Insight by Distribution Channel
On the basis of distribution channel, the market is subdivided into hospital pharmacies, online pharmacies and retail pharmacies. Among the all distribution channels, the retail pharmacies accounted the largest share in the human recombinant insulin market, as it offers extensive range of diabetic products including over-the-counter and prescription drugs for the diabetic patients.
Insight by Application
On the basis of application, the market is subdivided into type I diabetes and type II diabetes. Type I diabetes accounts for about 5 to 10 percent of the diabetes cases and type II accounts for approximately 90 percent of the diabetic cases. Many patients with type II diabetes are asymptomatic. Among the both applications, the type II diabetes accounted the largest share in the human recombinant insulin market due to mounting incidence of type II diabetes. For instance, according to International Diabetes Federation (IDF) in 2017, globally approximately 352 million people were at risk of developing type II diabetes.
Mounting number of diabetic patients, promising medical reimbursement setup in developed countries, escalating risk factors leading to diabetes, intensifying market availability of generic human insulin products and mounting need for human insulin analogs are the primary growth drivers for human recombinant insulin market. For instance, according to World Health Organization (WHO), globally the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. In addition, according to IDF in 2017, globally approximately 425 million adults were suffering from diabetes and are expected to reach 629 million in 2045.
Expected patent expiry of major human analog drugs, expanding geriatric population, mounting R&D for drug discovery & development and technological advancement in human insulin delivery devices are also facilitating the growth for the human recombinant insulin market.
Mounting government schemes to support the expansion and commercialization of efficient biosimilars are also driving the growth of the market. For instance, several government and private research organizations are involved in R&D activities for evolving innovative treatment in diabetes care to upsurge the efficacy of human insulin, decrease diabetes affliction, and diminish the threat of diabetes related disorders.
Elevated product manufacturing cost and strict regulatory requirement for the sanction of the products are the major challenges for the growth of human recombinant insulin market.
Globally, the manufacturing companies trying to enter the human recombinant insulin market are required to maintain stringent regulatory standards. Moreover, the high level of capital requirement also poses a major barrier for the entry of new players. This offers an edge to the established players in the industry competition.
Geographically, North America is the largest human recombinant insulin market as in the region the number of diabetic patients is increasing. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015 approximately 23.1 million people in the U.S. had diabetes. Expanding geriatric population and technological advancement in the insulin delivery devices are also up surging growth of the North American human recombinant insulin market.
Asia-Pacific is observed to witness fastest growth in the market, due to mounting number of diabetic patients. In addition, mounting healthcare expenditure, developing regulatory skeleton for promoting approvals & medical repayments, reinforcing distribution networks of product manufacturers and expanding awareness about diabetes are also creating a positive impact on the human recombinant insulin market growth in the region.
Key players in the human recombinant insulin market are catering the demand of these devices by investing on technologically advanced products in their product portfolio across the globe. In August 2018, Novo Nordisk A/S acquired Ziylo, to accelerate development of glucose responsive insulin for therapeutic and diagnostic applications. Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Wanbang Biopharmaceuticals Co., Ltd., Bioton S.A., Eli Lilly and Company, Zhuhai United Laboratories Co., Ltd., Julphar Gulf Pharmaceutical Industries, Dongbao Enterprise Group Co., Ltd, and Gan & Lee Pharmaceuticals, Ltd. are the key players offering human recombinant insulin products.